Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Defibrotide for SARS-CoV2 ARDS
NCT04530604Phase 1Completed
- Start
- Oct 2020
- Primary completion
- Mar 2021
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of defibrotide in COVID-19 pneumonia and acute respiratory distress syndrome (ARDS). Primary endpoint: Number of Major Hemorrhagic Complications Within 14 Days of Initiation of Treatment. Started Oct 2020; status: completed.
02
Drugs
defibrotide
03
Conditions
COVID-19 pneumoniaacute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04530604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04530604.